CD274 and neoplasm: Combined nanoparticles co-loaded with TH-302 and an anti-PD-L1 antibody significantly reduced tumor volume (P < 0.01 vs. anti-PD-1 group) and tumor weight (P < 0.001 vs. anti-PD-1 group).